Peer-Reviewed Publication
JAMA Oncol2026June 25, 2026Journal Article
Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2-Positive Breast Cancer: A Secondary Analysis of the DAPHNe Trial.
Paolo Tarantino1,2,3, Tianyu Li4, Esther Ritah Ogayo2, Tasnim Rahman2, Molly K DiLullo2, Ashka Patel2, Sherif El-Refai5, Charles Abbott5, Bailiang Li5, Sean M Boyle5, Richard O Chen5, Neelam V Desai6, Laura M Spring7, Nadine M Tung6, Natalie Sinclair1,2, Meredith Faggen1,2, Michael Constantine1,2, Tari A King2,3,8, Ian E Krop9, Nabihah Tayob2, Elizabeth A Mittendorf2,3,8, Sara M Tolaney1,2,3, Eric P Winer9, Heather A Parsons1,2,3,10, Adrienne G Waks1,2,3
1Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
2Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, Massachusetts.
3Harvard Medical School, Boston, Massachusetts.
4Data Science, Dana-Farber Cancer Institute, Boston, Massachusetts.
5Personalis Inc., Fremont, California.
6Beth Israel Deaconess Medical Center, Boston, Massachusetts.
7Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston.
8Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, Massachusetts.
9Yale Cancer Center, New Haven, Connecticut.
10Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
Abstract
IMPORTANCE: The neoadjuvant combination of paclitaxel, trastuzumab, and pertuzumab (THP) represents a promising abbreviated regimen for early-stage ERBB2-positive breast cancer, but long-term outcomes and the role of ultrasensitive circulating tumor DNA (ctDNA) monitoring remain incompletely defined.
OBJECTIVE: To assess 5-year outcomes and characterize ctDNA dynamics with an ultrasensitive assay…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans